Alterations in the composition of the plasma lipids caused by estrogens are characterized by an increase in the high-density lipoproteins (HDL) 
Introduction
Estrogens decrease hepatic oxidation of adipose tissue lipid to ketones and increase synthesis of triglycerides. Estrogens increase serum triglycerides and free and esterified cholesterol. Phospholipids are also increased, as are HDL; levels of LDL usually decrease. Although the effects are marked with doses of 100 mcg of mestranol or ethinyl estradiol, doses of 50 mcg or less have minimal effects. The progestins (particularly the "19-nortestosterone" derivatives) tend to antagonize these effects of estrogen. Preparations containing small amounts of estrogen and a progestin may slightly decrease triglycerides and HDL. 1 The effect of oestrogens is on balance favorable, but the addition of a progestogen (unless gestodene or desogestrel) reverses the balance.
2 Estrogens have many effects on lipid metabolism; of major interest are their effects on serum lipoprotein and triglyceride levels. 3 In general, estrogens slightly elevate serum triglycerides and slightly reduce total serum cholesterol levels. More importantly, they increase HDL levels and decrease the levels of LDL and Lipoprotein A. The presence of estrogen receptors in the liver suggests that the beneficial effects of estrogen on lipoprotein metabolism are due partly to direct hepatic actions. 4 Progesterone stimulates lipoprotein lipase activity and seems to enhance fat deposition. Progesterone and analogs such as Medroxy Progesterone Acetate (MPA) have been reported to increase LDL and cause either no effects or minimum reductions in serum HDL levels. The 19-norprogestins may have more pronounced effects on plasma lipids because of their androgenic activity. In this regard, a large prospective study has shown that MPA decreases the favorable HDL increase caused by conjugated estrogens during postmenopausal hormone replacement, but does not significantly affect the beneficial effect of estrogens to lower LDL. In contrast, micronized progesterone does not significantly affect beneficial estrogen effects on either HDL or LDL profiles.
5 In African-American women, OCP use is associated with an increase in markers of cardiovascular risk manifested by increased insulin resistance, glucose intolerance, and elevated TGs. 6 An open, prospective, noncomparative study of a contraceptive combination of ethinyl estradiol (30 µg) and gestating (75 µg) continuously for 24 weeks in 45 women aged 25±3.7 years revealed a reduction in the levels of cholesterol and LDL and an increase in HDL and triglycerides in Sao Paulo.
7
The different oral contraceptives available in Bangladesh have different doses of oestrogen and progesterone, therefore in this study we analysed the effect of two combined oral contraceptives on lipid profile.
Materials and Methods
This study was carried out in different Gynaecology outdoor chambers of private practitioners in Dhaka. Only those patients who were advised to do lipid profile by the gynaecologists before and after using OCP were enrolled in the study. Healthy subjects (n=68) aged within the reproductive age group 18 to 45 with no history of cardiovascular diseases were included in this study. Subjects using lipid lowering agents, steroids or other hormonal preparations were excluded from this study. After the subjects were advised to do lipid profile we gathered the data by questionnaire. Bangladesh Medical Journal 2011 Vol. 40, No.3 September 2011 Samples with preexisting hyperlipidaemia were also excluded from the study. After 3 months when these subjects came for follow up in Gynaecology outdoor and were again advised to do a lipid profile we recorded the data once more. Statistical analysis was performed using SigmaStat 3. 1 (San Jose, CA). Descriptive statistical analysis was performed to examine the distribution of each of the major baseline and outcome variable. The effects of OCPs on serum lipid levels were analyzed by paired t-test. Correlation or differences was considered significant at P=<0.05
Results
Subjects with moderate socio economic status were recruited in this study. Sixty eight female subjects were advised to take either 30 mcg of oestrogen in the form of Ethinylestradiol and 150 mcg of progesterone in the form of Desogestrel or 0.05 mg of oestrogen in the form of Ethinylestradiol and 1 mg of progesterone in the form of Lynestrenol. The baseline characteristics of the subjects did not differ in age, years of education, family income, etc. between these two groups ( 
Discussion
OCP alone led to a 5% increase of total cholesterol without effect on low-density lipoprotein cholesterol in a study in Poland8. Studies on the use of oral contraceptives in the West have shown that they induce changes in total serum cholesterol, triglycerides, high density lipoproteins, low density lipoproteins, and very low density lipoproteins --Bangladesh Medical Journal 2011 Vol. 40, No. atherosclerosis. 9 In Bangladesh, however, women consume low fats, low cholesterol and fewer calories; they drink less alcohol and rarely smoke; and they engage in more physical activities.
2 groups of Bangladeshi women were tested for lipid metabolism alterations during and after use of oral contraceptives prescribed by gynaecologists.
1 group of 34 women received low dose oral contraceptives containing 30 mcg of Ethinylestradiol and 150 mcg of Desogestrel and their serum lipid levels were tested after 3 months of use. A 2nd group of 34 women received low dose oral contraceptives containing 0.05 mg of Ethinylestradiol and 1 mg of Lynestrenol and their serum lipid levels were tested after 3 changes which are implicated in the development of months of use. Results showed that both the OCPs decreased the serum cholesterol level (P<0.0001) and serum LDL level (P<0.0001), while increased serum HDL level (P<0.0001). But the increase in serum triglyceride was not significant. BMI increased in both the groups which was also statistically significant.
Conclusion
The findings of both OCP reinforce the need to monitor changes in these factors within the context of the treated patient's risk-benefit profile. However, because the magnitude of these differences was small, relative to normative ranges, it may be concluded that OCPs are unlikely to markedly affect cardio metabolic risk. In conclusion, to the best of current knowledge, in this area, this is the first study of OCP on lipid profile in Bangladesh. Although sample size is low (n=68), more studies with larger sample size are required to verify the repeatability of these findings. 
